ImmunoCellular Jumped On positive Data (IMUC, MW, RDN, SPA, AIR)

ImmunoCellular Therapeutics Ltd (NYSEAMEX: IMUC) surged up 11.72% to $3.24. The Company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma. A total of 278 patients at 25 participating sites have been enrolled in this trial, which was initiated in January 2011.

Will IMUC Continue To Move Higher? Find Out Here

The Men's Wearhouse Inc (NYSE:MW) among the gainers 15.33% to $36.72 on a traded volume of 1.79 million shares. The Company expects total sales increase in a range 8.8% to 9.3% for third quarter of 2012. GAAP diluted earnings per share in a range of $0.95 to $0.98 and comparable store sales growth of +8% to +9% for third quarter. The Company expects total sales increase in a range 11.3% to 11.8%, GAAP diluted earnings per share in a range of $0.12 to $0.15 and comparable store sales growth of +3% to +4% for fourth quarter of 2012.

Radian Group Inc (NYSE:RDN) is one of the top percentage gainer and surged up 18.79% to $ 3.92 in the early trading hours. The Company released data for primary mortgage insurance delinquencies for August 2012. New mortgage insurance business increased to $3.75 billion. The Company realizes $120 million in investment gains to support risk-to-capital position.

Has RDN Found The Bottom? Find Out Here

Sparton Corporation (NYSE:SPA) jumped up 9.66% to $11.12 on a traded volume of 83k shares. The Company reported fourth quarter net income of $4.05 million or $0.40 per share compared to net loss of $0.7 million or $0.07 per share in the prior year period.Net sales for the latest quarter was $61.3 million from $60.9 million last year.

AAR Corp (NYSE:AIR) one of the top gainers in the morning session. The stock increased 10.97% to $16.19 after the Company said that it expects fiscal first quarter earnings and revenue will beat Wall Street's expectations. The Company expects earnings of 42 cents to 45 cents per share for the period. The company anticipates revenue in a range of $540 million to $550 million. However, analysts expect earnings of 33 cents per share on revenue of $524.8 million.  The Company will report its first-quarter financial results on September 19, 2012.